



REINSURANCE **HOT NEWS**

August 12TH, 2026

AHCCCS is pleased to announce the addition of the following drug to the High-Cost Specialty Drug Reinsurance (BIO) effective:

Effective October 1, 2026:

Lumvoa-(Veligrotug-vvze)- An insulin- like growth factor-1 receptor inhibitor indicated for the treatment of thyroid eye disease.

Updated verbiage- for Papzimeos

(Indicated for the treatment of adults with recurrent respiratory papillomatosis)

Reminder from the Reinsurance Manual (Page 20)

"For multiple reinsurance drugs to treat the same medical condition, please refer to the AHCCCS Fee For Service prior authorization criteria to determine if the criterion supports the use of multiple medications given/administered at the same time to an individual. When the prior authorization criterion is not supportive of the use of multiple drugs to treat the same condition, the reinsurance program will not reimburse multiple medications. For additional

questions, please check with the Medical Management staff assigned to the MCO. "

Here is the Link to the Updated High-Cost Specialty Drug List:
<https://www.azahcccs.gov/PlansProviders/Downloads/Reinsurance/BiologicandHighCostSpecialtyDrugList.xlsx>